Press release
Pancreatic Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pha
Pancreatic Cancer Pipeline Insights
Pancreatic Cancer Overview:
Pancreatic cancer occurs when malignant cells develop in the pancreas, an organ located behind the stomach. It typically originates from pancreatic intraepithelial neoplasia (PanIN), a common pre-cancerous lesion, but can also arise from larger precursor lesions like intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms. The cancer is characterized by abnormal signaling that promotes the proliferation, migration, invasion, and metastasis of cancer cells.
In addition, pancreatic cancer involves metabolic changes and resistance to growth-inhibiting signals. One example of this is the abnormal TGFβ signaling pathway. Although TGFβ usually acts as a tumor suppressor, its increased expression in pancreatic cancer contributes to tumor progression by stimulating growth and metastasis. TGFβ can also promote cancer cell proliferation through non-canonical signaling pathways, involving MAPK phosphorylation, Src, AKT, and WNT7B, which help drive cancer development.
Request for a detailed insights report on Pancreatic Cancer pipeline insights @ https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
"Pancreatic Cancer Pipeline Insight 2024" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Pancreatic Cancer Therapeutics Market.
Key Takeaways from the Pancreatic Cancer Pipeline Report
DelveInsight's Pancreatic Cancer pipeline report depicts a robust space with 290+ active players working to develop 300+ pipeline therapies for Pancreatic Cancer treatment.
In December 2024, Zai Lab Limited and Novocure announced that the Phase 3 PANOVA-3 trial successfully met its primary endpoint, demonstrating a statistically significant improvement in median overall survival (mOS) compared to the control group. The trial evaluated the combination of Tumor Treating Fields (TTFields) therapy with gemcitabine and nab-paclitaxel as a first-line treatment for unresectable, locally advanced pancreatic adenocarcinoma.
Key Pancreatic Cancer companies such as ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc, ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics, and others are evaluating new drugs for Pancreatic Cancer to improve the treatment landscape.
Promising Pancreatic Cancer pipeline therapies in various stages of development include Pamrevlumab, Devimistat, Masitinib, SBP-101, TAS-102, RAIN-32, IMX-110, and others.
Pancreatic Cancer Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Pancreatic Cancer Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Pancreatic Cancer treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Pancreatic Cancer market.
Download our free sample page report on Pancreatic Cancer pipeline insights @ https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Pancreatic Cancer Emerging Drugs
Pamrevlumab: FibroGen
Devimistat: Cornerstone Pharmaceuticals
Masitinib: AB Science
SBP-101: Panbela Therapeutics
TAS-102: Taiho Pharmaceutical Co., Ltd.
RAIN-32: Rain Oncology
IMX-110: Immix Biopharma
Pancreatic Cancer Companies
More than 290 major companies are involved in developing treatments for pancreatic cancer. FibroGen is one of these companies, with drug candidates for pancreatic cancer currently in the advanced Phase III stage.
DelveInsight's report covers around 300+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Pancreatic Cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Pancreatic Cancer Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Pancreatic Cancer Therapies and Key Companies: Pancreatic Cancer Clinical Trials and advancements @ https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Pancreatic Cancer Pipeline Therapeutic Assessment
• Pancreatic Cancer Assessment by Product Type
• Pancreatic Cancer By Stage
• Pancreatic Cancer Assessment by Route of Administration
• Pancreatic Cancer Assessment by Molecule Type
Download Pancreatic Cancer Sample report to know in detail about the Pancreatic Cancer treatment market @ Pancreatic Cancer Therapeutic Assessment @ https://www.delveinsight.com/sample-request/pancreatic-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Table of Content
1. Report Introduction
2. Executive Summary
3. Pancreatic Cancer Current Treatment Patterns
4. Pancreatic Cancer - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Pancreatic Cancer Late-Stage Products (Phase-III)
7. Pancreatic Cancer Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Pancreatic Cancer Discontinued Products
13. Pancreatic Cancer Product Profiles
14. Pancreatic Cancer Key Companies
15. Pancreatic Cancer Key Products
16. Dormant and Discontinued Products
17. Pancreatic Cancer Unmet Needs
18. Pancreatic Cancer Future Perspectives
19. Pancreatic Cancer Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Pancreatic Cancer Pipeline Reports Offerings: https://www.delveinsight.com/report-store/pancreatic-cancer-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Contact Info:
Kritika Rehani
krehani@delveinsight.com
info@delveinsight.com
+14699457679
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Pancreatic Cancer Clinical and Non-Clinical Studies, Key Companies, Therapeutic Assessment, Emerging Therapies, Treatment Algorithm, and Pipeline Analysis | ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pha here
News-ID: 3816584 • Views: …
More Releases from DelveInsight Business Research LLP
Gonorrhoea Pipeline Outlook Report 2025: MOA, Companies, Companies, Clinical Tri …
DelveInsight's "Gonorrhoea Pipeline Insight 2025" report provides comprehensive insights about 12+ companies and 12+ pipeline drugs in the Gonorrhoea pipeline landscape. It covers the Gonorrhoea pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Gonorrhoea pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive Gonorrhoea pipeline products in this space.
Explore our latest breakthroughs in Gonorrhoea Research. Learn…
Glioblastoma Multiforme Market Size (7MM) was ~USD 835 million in 2023 and is ex …
DelveInsight's "Glioblastoma Multiforme Market Insight, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of GBM, historical and forecasted epidemiology as well as the GBM market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Discover Key Insights into the Glioblastoma Multiforme Market with DelveInsight's In-Depth Report @ Glioblastoma Multiforme Market Size- https://www.delveinsight.com/sample-request/glioblastoma-multiforme-gbm-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from the Glioblastoma Multiforme Market Report
• In…
Blepharitis Treatment Market Size in the 7MM is expected to grow by 2034, estima …
DelveInsight's "Blepharitis Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Blepharitis, historical and forecasted epidemiology, as well as the Blepharitis market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Explore the intricate details of the Blepharitis Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Blepharitis Market Forecast @ https://www.delveinsight.com/sample-request/blepharitis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Key Takeaways from…
CAR-T in NHL Treatment Market Size is estimated to grow by 2034, estimates Delve …
DelveInsight's "CAR T-Cell Therapy for Non-Hodgkin's Lymphoma Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of CAR T-Cell Therapy for Non-Hodgkin's Lymphoma, historical and forecasted epidemiology, as well as the CAR T-Cell Therapy for Non-Hodgkin's Lymphoma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.
Explore the intricate details of the CAR T-Cell Therapy for Non-Hodgkin's Lymphoma…
More Releases for Pancreatic
Pancreatic Cancer Diagnostic Market Surges In Response To Escalating Prevalence …
Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Pancreatic Cancer Diagnostic Industry Market Size Be by 2025?
The sector dedicated to diagnosing pancreatic cancer has experienced significant upward momentum lately, projecting an expansion from a valuation of $4.24 billion in 2024 to $4.54 billion in 2025, reflecting a steady compound annual growth rate of…
Growing Pancreatic Cancer Cases : Pivotal Factor Influencing Pancreatic Cancer D …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
Pancreatic Cancer Drugs Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market size for pancreatic cancer drugs has seen consistent growth over the past few years. An escalation from $3.96 billion in 2024 to $4.1 billion in 2025 is projected, marking a compound annual…
Pancreatic Cancer Diagnostic Market Surges In Response To Escalating Prevalence …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Is the Expected CAGR for the Pancreatic Cancer Diagnostic Market Through 2025?
The market size for pancreatic cancer diagnostics has been witnessing robust growth in recent times. There will be a growth from $4.24 billion in 2024 to $4.55 billion in 2025, showcasing a Compound Annual Growth Rate…
Pancreatic Cancer Diagnostic Market Surges In Response To Escalating Prevalence …
The Pancreatic Cancer Diagnostic Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Pancreatic Cancer Diagnostic Market Size and Projected Growth Rate?
There has been a significant expansion in the pancreatic cancer diagnostic market recently. This market is projected to increase from a value…
Pancreatic Amylase Reagent Kits: Streamlining Enzyme Analysis for Efficient Panc …
Pancreatic Amylase Reagent Kits Market 2023 Forecast: Unveiling Opportunities and Growth
Pancreatic Amylase Reagent Kits Market research report helps to recognize the market challenges and opportunities. Global Pancreatic Amylase Reagent Kits Market report contains the recent forecast research for the predicted period. The report extensively offers the latest information about the technological developments and market growth prospect on the basis of the regional landscape. This Report offers a complete evaluation of…
Pancreatic Cancer Therapy Market: Rise in Number of Patients Suffering with Panc …
Pancreatic cancer is one of the aggressive cancers that originate in the tissues of the pancreas and rapidly spreads to the nearby organs. Pancreatic cancer is the 12th most commonly occurring cancer in the world. According to the American Cancer Society, ~55,440 patients in the US are expected to be diagnosed with pancreatic cancer in 2018. Moreover, the ACS also reports that pancreatic cancer is the third leading cause of…
